bimosiamose has been researched along with Dizziness* in 1 studies
1 trial(s) available for bimosiamose and Dizziness
Article | Year |
---|---|
Physiochemical properties, safety and pharmacokinetics of bimosiamose disodium after intravenous administration.
Bimosiamose is a novel synthetic panselectin antagonist being developed for the treatment of acute and chronic inflammatory disorders. Therefore, we have studied the pharmacokinetics and tolerability and determined the pharmacokinetically relevant physicochemical characteristics of bimosiamose.. A randomized, double-blind, placebo-controlled dose-escalation trial in healthy male subjects has been carried out. The subjects received intravenous infusions of 0.5-30 mg/kg bimosiamose disodium.. The maximum plasma concentration (Cmax) was 675 +/- 11 microg/ml with a tmax of 0.36 +/- 0.13 h (mean +/- SD). The elimination half-life t1/2 was 4.1 +/- 1.0 h, and the AUC(o-inf) was 1,360 +/- 393 h microg/ml after the 30 mg/kg dose. The clearance and the apparent volume of distribution decreased with increasing dose to 22 +/- 6 ml/kg/h and 40 +/- 13 ml/kg/h at the highest dose, respectively, and the mean residence time increased to 1.8 +/- 0.35 h. Bimosiamose was safe and well-tolerated. Topics: Adult; Area Under Curve; Dermatitis, Contact; Dizziness; Dose-Response Relationship, Drug; Double-Blind Method; Half-Life; Hexanes; Humans; Hydrogen-Ion Concentration; Infusions, Intravenous; Male; Mannose; Metabolic Clearance Rate; Molecular Structure; Solubility | 2005 |